Dopamine News and Research

RSS

Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.

New understanding of schizophrenia

New research helps bridge an important gap in understanding schizophrenia, providing the best evidence to date that defects in the brain's white matter are a key contributor to the disease, which affects about 1 percent of people worldwide.

24 Apr 2007

Online gambling adds new risks for gamblers with Parkinson's disease

Parkinson's disease sufferers could be adversely affected by the growth of betting on the web because they are more likely to become gambling addicts, says a doctor writing in the British Medical Journal.

20 Apr 2007

Jefferson participates in global study to extend effectiveness of drug for Parkinson's

After Parkinson's disease patients use the drug levodopa or L-dopa for several years as a treatment for restoring the cellular communication that controls muscle movement by replacing lost dopamine, they begin to experience motor complications that include a shortened response to each dose of L-dopa.

19 Apr 2007

Stroke damage in a brain region known as the putamen is strongly linked to motor neglect

Scientists have untangled two similar disabilities that often afflict stroke patients, in the process revealing that one may be treatable with drugs for Parkinson's disease.

4 Apr 2007

Protein alpha synuclein plays important role in regulation of dopamine function

SNCA mutations can lead to significant problems, such as the neurodegenerative disorder Parkinson's disease, which is caused by a substantially reduced production of dopamine.

3 Apr 2007

New treatment possibilities for Huntington's disease

Howard Florey Institute have opened up new treatment possibilities for Huntington's disease by proving a scientific theory incorrect.

3 Apr 2007

Withdrawal of Pergolide products

The U.S. Food and Drug Administration (FDA) today announced that manufacturers of pergolide drug products, which are used to treat Parkinson's disease, will voluntarily remove these drugs from the market because of the risk of serious damage to patients' heart valves.

29 Mar 2007

Researchers look at whether creatine slows progression of Parkinson's disease

Researchers at the University of Rochester Medical Center are leading one of the largest clinical trials ever for Parkinson's disease.

25 Mar 2007

Circadian genes may be involved in bipolar disorder

Disrupt the gene that regulates the biological clocks in mice and they become manic, exhibiting behaviors similar to humans with bipolar disorder, UT Southwestern Medical Center researchers have found.

25 Mar 2007

Creatine may help Parkinson's patients by giving an energy boost to dying cells

Whether a supplement used by athletes to boost energy levels and build muscle can slow progression of Parkinson's disease is the focus of a North American study.

22 Mar 2007

New understanding of drug addiction

The reason why some individuals may be predisposed to drug addiction has been discovered by scientists from the universities of Bristol and Cambridge.

1 Mar 2007

Smoking produces biochemical changes in human brain

New research shows for the first time that smoking produces long-lasting biochemical changes in the human brain similar to those changes previously seen in the brains of animals that used cocaine, heroin, and other illicit drugs.

20 Feb 2007

Genetic variations contribute to a person's risk for nicotine dependence

Americans are bombarded with antismoking messages, yet at least 65 million of us continue to light up. Genetic factors play an important role in this continuing addiction to cigarettes, suggest scientists at Washington University School of Medicine in St. Louis.

18 Feb 2007

Therapy for restless legs may trigger compulsive gambling

Compulsive gambling with extreme losses -- in two cases, greater than $100,000 -- by people without a prior history of gambling problems has been linked to a class of drugs commonly used to treat the neurological disorder restless legs syndrome (RLS).

11 Feb 2007

CeNeRx BioPharma starts human trials of RIMA antidepressant

CeNeRx BioPharma, Inc. has announced the initiation of human clinical trials of Tyrima, CeNeRx's new drug candidate with a triple mechanism of action for the treatment of depression and anxiety.

30 Jan 2007

Canadian researchers discover distinct dopamine signalling complex in the brain

Composed of two different types of dopamine receptors, this novel target may have a significant role in understanding and treating schizophrenia.

23 Jan 2007

Cell therapy for Parkinson's

Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.

8 Jan 2007

Human embryonic stem cells show potential in treating rats with Parkinson's symptoms

Brain cells derived from human embryonic stem cells improved the condition of rats with Parkinson's-like symptoms dramatically, but the treatment caused a significant problem - the appearance of brain tumors - that scientists are now working to solve.

2 Dec 2006

High dopamine transporter levels not linked to attention-deficit hyperactivity disorder

Results from a brain-imaging study conducted at the U.S. Department of Energy's Brookhaven National Laboratory in collaboration with Mount Sinai School of Medicine in New York indicate that levels of a brain protein proposed as a diagnostic marker for attention-deficit hyperactivity disorder (ADHD) are not positively correlated with the disease.

2 Dec 2006

UIC study evaluates two medications for ADHD

University of Illinois at Chicago researchers are comparing two drugs commonly used to treat attention deficit hyperactivity disorder to determine if genetic factors predict which children will respond to either or both drugs.

7 Nov 2006